J&J's Tremfya Shows Sustained Remission In Crohn's Disease Through 3 Years
(RTTNews) - Johnson & Johnson (JNJ) reported three-year data showing sustained clinical and endoscopic remission with Tremfya (guselkumab) in adults with moderately to severely active Crohn's disease.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.